* Ranking in top 1% of S&P Global CSA Score * Inclusion in Global Yearbook for third consecutive...
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysog...
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...
WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...
* Ranked among the top 1% of more than 150,000 companies across 185 countries * Trusted by globa...
* Ranked among the top 1% of companies assessed in the pharmaceutical industry * Recognized as a ...
SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a lead...
* Named for second consecutive year named to prestigious DJSI list * Leading green biologics sol...
* Leading Green CRDMO Driven by Innovation for a Healthier Future * Offering End-to-end Green Bi...
SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...
HONG KONG, Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...
Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-CO...
* Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characteri...
WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leadi...
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
* The Company demonstrated a deep commitment to achieving ESG success in partnership with global ...
Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Mi...
SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
* Named Top-Rated for fourth consecutive year * Committed to generating long-term value for all ...